PIYUSH GUPTA, PhD
Co-Founder, CEO & Chairman
Dr. Gupta earned his bachelor’s degree in Mathematics from the University of Chicago and a PhD in Cancer Biology from MIT. Dr. Gupta was a member of the Whitehead Institute for Biomedical Research and an Associate Professor of Biology at MIT. Dr. Gupta previously co-founded Verastem, Inc., based on his scientific research at MIT and served as a Director on its corporate board from founding through multiple rounds of venture capital financing and an IPO. His research has appeared in leading scientific journals and received international acclaim, including coverage by the MIT Technology Review, Bloomberg News, and as a lead story in the New York Times.
BARRY M. BERGER, MD FCAP
Chief Medical Officer
Barry M. Berger MD FCAP was the Chief Medical Officer for Exact Sciences Corporation for 20 yrs, and developed advanced DNA based tests for colorectal cancer screening. Prior to Exact, Dr. Berger’s clinical career was spent at the Department of Pathology and Laboratory Medicine of Harvard Pilgrim Healthcare. Dr. Berger is the past chairman of the Advisory Committee on Clinical Laboratories for the Commonwealth of MA and is a currently serves on the Executive Committee of the Massachusetts Society of Pathologist and the Policy Committee of the National Colorectal Cancer Roundtable. He has served as a panelist for the Medicare Evidence Development and Coverage Advisory Comm. He received his MD from the University of Pennsylvania followed by a post-doctoral fellowship in Immunology with Dr. Peter Nowell. Following a medical internship at Boston University Hospital, and 2 years as a general medical officer in the USAF, he completed a Residency/Chief Residency in Pathology at Brigham and Women’s Hospital.
PHIL STEPHENS, PhD
Chief Scientific Officer
Dr. Stephens is a world-renowned expert in next-generation sequencing and cancer genome analysis and brings a breadth of experience in life sciences and the clinical diagnostics and laboratory industries. Dr. Stephens was Chief Scientific Officer at Foundation Medicine Inc (FMI) for 5 years where he oversaw the development of comprehensive next generation sequencing cancer diagnostic assays in the CLIA setting. During his seven years at FMI, he also played an integral role in securing reimbursement of their novel products, driving 30+ Pharmaceutical collaborations and the FDA approval coupled with Medicare reimbursement of FoundationOneTM. Prior to joining Naveris, Dr. Stephens was Chief of Cancer Biology at Grail.
THOMAS K. LIEM, MST MBA
Senior Vice President,Finance & Business Operations
Thomas K. Liem is Senior Vice President of Business Operations & Finance. Prior to joining Naveris, Mr. Liem was at Thomas H. Lee Partners for seven years where he managed financial reporting, portfolio monitoring, fundraising and operations initiatives and was an integral part of the firm’s fundraising efforts. He has over 20 years of finance and business operations experience at companies such as Nuance Communications, State Street Corporation, Fidelity Investments, The MathWorks Inc, Percussion Software, The World Bank and The Hackett Group. Mr. Liem received his BA with honors from Hamilton College, an MBA from Babson College F.W. Olin Graduate School of Business and an MS in Taxation from Suffolk University, where he was a Graduate Fellow
PHILIP HAYDON, PhD
Dr. Haydon is the Annetta and Gustav Grisard Professor and Chair in the Department of Neuroscience at Tufts. He is an internationally recognized leader in the study of neuron-glial interactions in disease. He has received several prestigious awards, including a McKnight Investigator Award and the Jacob Javits Award from the National Institutes of Neurological Disorders and Stroke. Dr. Haydon was a founder and partner in Prairie Technologies, a privately held company that developed state-of-the-art microscopy tools including 2 Photon microscopes for use in the neurosciences. Prairie Technologies was subsequently acquired by Bruker Instruments. He was also co-founder and President of GliaCure, Inc., which has developed a small molecule modulator of the P2Y6R as a potential therapeutic for Alzheimer’s disease and asthma. Dr. Haydon has taken this company through successful rounds of fund raising and has overseen preclinical and clinical development of the compounds.
STEPHEN NABER, MD PhD
Stephen Naber, MD, PhD is Laboratory and Medical Director. Dr. Naber is a Board certified Anatomic Pathologist with expertise in cancer diagnostics. Prior to joining Naveris, Dr. Naber served as the Chief of Pathology at Tufts Medical Center and was Director of its CLIA & CAP accredited diagnostic lab. Dr. Naber serves as an Associate Chair in the Department of Pathology at Tufts University School of Medicine, and has had a long and illustrious teaching and research career spans more than two decades. He serves as Member of Scientific Advisory Board of BioLegend CNS, Inc. He has been the recipient of several National Institutes of Health and Department of Defense grants and awards for studies in studies of breast neoplasia, models of tumor development, and regulation of gene expression in human breast cancer. Dr. Naber received his MD from St. Louis University School of Medicine and his PhD in Physiology from the University of Houston.
CHARLOTTE KUPERWASSER, PhD
Dr. Kuperwasser is a Professor of Developmental, Molecular & Chemical Biology and Director of the Raymond & Beverly Sackler Convergence Laboratory at Tufts University School of Medicine. She has over 20 years of experience in leading cancer R&D laboratories. Dr. Kuperwasser pioneered the development of innovative models of cancer and discovered biomarkers for early detection of breast cancer. Dr. Kuperwasser received her PhD at the University of Massachusetts, Amherst, and was a Jane Coffin Child’s Postdoctoral Fellow at the Whitehead Institute for Biomedical Research at MIT. She has also been a Howard Hughes Fellow, a Merck Fellow, and received multiple awards for her research including the ECOG/Aventis Young Investigator Award. She has authored more than 100 publications and serves as an external editor and reviewer for multiple scientific journals, the National Institutes of Health, and the American Cancer Society.
GAORAV GUPTA, MD PhD
Inventor & Co-Chair, Scientific Board of Advisors
Dr. Gaorav Gupta is a UNC Lineberger Comprehensive Cancer Center member and Assistant Professor in the Division of Radiation Oncology at UNC-Chapel Hill School. He received his M.D. and Ph.D. from Weill Cornell Medical College of Cornell University. He was Chief Resident in Radiation Oncology at Memorial Sloan Kettering Cancer Center and was among the few 2013 recipients of the Burroughs Wellcome Fund Career Award for Medical Scientists. Dr. Gupta lab studies DNA repair processes in cancer development, metastatic progression, and responses to therapy.
BHISHAM CHERA, MD
Co-Chair, Scientific Board of Advisors
Bhisham Chera, MD is an Associate Professor and Associate Chair in the Department of Radiation Oncology at the University of North Carolina School of Medicine. He received his M.D. from the Medical University of South Carolina. He is the leader of the head and neck radiation oncology program at the University of North Carolina School of Medicine and a clinical trials specialist and with clinical and academic expertise is in the field of head and neck oncology and healthcare quality improvement and patient safety. Dr. Chera has conducted three phase II clinical trials evaluating de-intensified chemoradiotherapy, and pioneered the innovation of treating patients with a substantial reduction of both radiation and chemotherapy.
ROBERT WEINBERG, PhD
Dr. Robert A. Weinberg
Michael J Cohen, J.D.
Legal (Brown Rudnick)
Michael Cohen represents early stage and mid-market companies as well as venture, hedge, and private equity funds in connection with mergers and acquisitions, joint ventures and strategic alliances, financing transactions and general corporate and commercial matters at all stages of the corporate life cycle.